ArticlePloS one2026
Comparison of different glycemic control indicators on incidence of acute kidney injury and long-term mortality in critically ill patients with atherosclerotic cardiovascular disease: A retrospective cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced glycemic metrics may better reflect glucose dysregulation in critically ill patients than conventional indicators, but their comparative predictive value for adverse outcomes in atherosclerotic cardiovascular disease (ASCVD) patients remains unclear.
methodsThis retrospective study using the MIMIC-IV database assessed associations between stress hyperglycemia ratio (SHR), hemoglobin glycation index (HGI), and glycemic variability (GV) with acute kidney injury (AKI) and 365-day mortality in 2,820 ASCVD patients. Multivariable regression models, restricted cubic splines, and ROC curves evaluated predictive performance.
resultsDuring ICU stay, 38.4% developed AKI, and 17.9% died within one year. GV showed the strongest association with both AKI (Q4 vs. Q1, OR=4.98, 95%CI:3.00-8.26, P < 0.001) and mortality (Q3 vs. Q1, HR = 1.77, 95%CI:1.19-2.63, P = 0.005). SHR was associated with increased AKI risk (Q4 vs. Q2, OR=1.47, 95%CI:1.12-2.19, P = 0.04) and mortality (Q4 vs. Q2, HR = 1.26, 95%CI:1.06-1.69, P = 0.01), while HGI showed inverse association with mortality (Q4 vs. Q1, HR = 0.71, 95%CI:0.53-0.93, P = 0.01). GV yielded the highest predictive accuracy for AKI (AUC = 0.69) and mortality (AUC = 0.62). Subgroup analyses confirmed robustness across demographics.
conclusionsAmong critically ill ASCVD patients, GV outperformed SHR and HGI in predicting AKI and long-term mortality, underscoring its prognostic utility and supporting individualized glucose management in ICU settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.